Kosin Medical Journal

Case report

Congenital right ventricular aneurysm mimicking pericardial lymphadenopathy: a case report: Soo-Jin Kim, Eun-Ju Kang, Bong-Joon Kim, Sung-Il Im, Jung-Ho Heo, Hyun-Su Kim; Received May 11, 2026 Accepted June 29, 2026 Published online September 7, 2026; DOI: https://doi.org/10.7180/kmj.26.178 [Epub ahead of print]

302 View
2 Download

Abstract PDF Supplementary Material PubReader ePub: A 73-year-old male patient presented to our hospital with chronic cough. Chest computed tomography (CT) showed pericardial lymphadenopathy, and surgical removal was planned. During preoperative echocardiography, an anechoic cyst-like lesion was identified at the right ventricular (RV) apex that did not correspond to the CT finding. Further echocardiographic evaluation suggested communication between the RV and the lesion, and contrast echocardiography confirmed a congenital RV aneurysm. The patient had a history of stable angina. Review of previous records showed an anomalous origin of the left coronary artery from the right coronary sinus and prior coronary stent implantation in the right coronary artery for diffuse atherosclerosis. An RV apical aneurysm was also visible on CT obtained 9 years earlier, with little interval change in size; therefore, conservative monitoring was continued. Congenital RV aneurysm is rare. In this case, multimodal imaging enabled accurate diagnosis of a congenital RV aneurysm that had remained stable over 9 years.

Original article

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab: Su-Hyun Bae, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo; Kosin Med J. 2025;40(1):49-54. Published online March 27, 2025; DOI: https://doi.org/10.7180/kmj.24.145

20,645 View
73 Download
1 Citations

Background
The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and alirocumab has not been fully established. This study evaluated the lipid-lowering effects of these two PCSK9 inhibitors.
Methods
Patients diagnosed with ACS, including unstable angina, ST-segment elevation myocardial infarction, and non-ST-segment elevation myocardial infarction, who were treated with a PCSK9 inhibitor (evolocumab or alirocumab) during hospitalization for ACS between 2021 and 2023 were retrospectively analyzed. Baseline low-density lipoprotein cholesterol (LDL-C) levels were assessed, and changes in LDL-C levels during the acute and subacute phases after PCSK9 inhibitor administration were compared between the evolocumab and alirocumab groups.
Results
Among 80 patients diagnosed with ACS, 36 received evolocumab, while 44 were treated with alirocumab. The mean baseline LDL-C level was 123 mg/dL in the evolocumab group and 128 mg/dL in the alirocumab group (p=0.456). In the subacute phase, the mean follow-up LDL-C levels were 47.05 mg/dL in the evolocumab group and 49.5 mg/dL in the alirocumab group (p=0.585). The mean percentage reduction in LDL-C levels during the subacute phase was 60.41% in the evolocumab group and 58.51% in the alirocumab group (p=0.431). These differences were not statistically significant.
Conclusions
No significant differences were observed between evolocumab and alirocumab. LDL-C levels exhibited a similar trend, characterized by a rapid decline in the acute phase, followed by a slight rebound in the subacute phase.

Citations

Citations to this article as recorded by

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis
Weiwei Ding, Lingyao Sun, Yun Shi, Lei Tian
International Journal of Cardiology Cardiovascular Risk and Prevention.2026; 28: 200568. CrossRef

Case report

Disseminated Staphylococcus aureus infection and acute bacterial pericarditis: a case report: Su Hyun Bae, Song-Hyun Lee, Joon-Young Choi, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo; Kosin Med J. 2023;38(2):134-137. Published online August 16, 2022; DOI: https://doi.org/10.7180/kmj.22.021

6,261 View
79 Download
1 Citations

Abstract PDF PubReader ePub

We experienced a case of disseminated Staphylococcus aureus infection with bacterial pericarditis that progressed to septic shock and multiorgan failure despite pericardiocentesis and surgical removal of the original abscess with intensive antibiotic therapy. We report this case because of the patient’s very rare and remarkable echocardiographic findings and highly turbid pericardial effusion.

Citations

Citations to this article as recorded by

Case Report: Acute methicillin-sensitive Staphylococcus aureus pericarditis in a diabetic patient
Daniel J. Lim, Richard Lu, Edwin C. Y. Sng, Felix M. Uy, Wei L. Huang, Siang C. Chai, Anthony Yii, Ing X. Soo, Jenn N. Khoo, X. Ruan
Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search